United Therapeutics Corporation
United Therapeutics Corporation logo
UTHR

United Therapeutics Corporation (UTHR)

$258.710.37%

Market is closed
– opens on 8 PM, 31 Jan 2023
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$256.75
Day's Range
$260.98
$158.38
52-Week Range
$283.09
1 month return5.35%
3 month return12.22%
1 year return28.16%
5 year return45.49%

Analyst Recommendation

based on 18 analysts ratings

Buy
83%
Buy
11%
Hold
5%
Sell

Based on 18 Wall street analysts offering stock ratings for United Therapeutics Corporation(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 10.36%

Current

$258.71

Target

$285.5

Recommendation Trend

Based on 18 analyst

Current1M Ago3M Ago
Buy
15
9
14
Hold
2
0
2
Sell
1
1
1
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization11.8B
Book Value$100.13
Dividend Share0.0
Dividend Yield0.0%
Earnings Per Share (EPS)14.44
PE Ratio17.92
PEG Ratio1.02
Wall Street Target Price285.5

Valuation

Trailing PE17.92
Forward PE14.53
Price/Book (mrq)2.8
Enterprise Value11.0B
Enterprise Value/Revenue5.9
Enterprise Value/Ebitda11.1

Technicals

Beta0.67
50 Day MA270.24
200 Day MA231.38

Sustainability

Rating Date2019-01-01
Total Esg35.51
Total Esg Percentile53.55
Environment Score6.16
Environment Score Percentile9.0
Social Score24.94
Social Score Percentile9.0
Governance Score17.41
GovernanceScorePercentile9.0
Controversy Level2.0

Institutional Holdings

Vanguard Group Inc

9.68%

BlackRock Inc

9.49%

FMR Inc

6.53%

venBio Select Advisor LLC

6.42%

Renaissance Technologies Corp

5.6%

State Street Corporation

3.5%

Company Information

United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture and our bioinformatics leadership. We also believe that our determination to be responsible citizens - having a positive impact on patients, the environment and society - will sustain our success in the long term. Through our wholly-owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.
OrganizationUnited Therapeutics Corporation
Employees965
CEODr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
IndustryHealth Technology

Discover more

Frequently Asked Questions

What is United Therapeutics Corporation share price today?

Can Indians buy United Therapeutics Corporation shares?

How can I buy United Therapeutics Corporation shares from India?

Can Fractional shares of United Therapeutics Corporation be purchased?

What are the documents required to start investing in United Therapeutics Corporation stocks?

What are today’s High and Low prices of United Therapeutics Corporation?

What are today’s traded volumes of United Therapeutics Corporation?

What is today’s market capitalisation of United Therapeutics Corporation?

What is the 52 Week High and Low Range of United Therapeutics Corporation?

How much percentage United Therapeutics Corporation is down from its 52 Week High?

How much percentage United Therapeutics Corporation is up from its 52 Week low?

What are the historical returns of United Therapeutics Corporation?

Who is the Chief Executive Officer (CEO) of United Therapeutics Corporation?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*